Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
|Date||Event description||Earnings per|
|February 2, 2023||Q4 2022 Earnings Release||$1.82||$1.61 to $1.83||$1.83|
|October 25, 2022||Q3 2022 Earnings Release||$1.99||$1.74 to $1.91||$2.00|
|July 27, 2022||Q2 2022 Earnings Release||$1.93||$1.68 to $1.93||$1.93|
|April 29, 2022||Q1 2022 Earnings Release||$1.96||$1.74 to $1.97||$1.74|
|Ex-dividend date||Amount||Record date||Pay date|
|January 5, 2023||$0.57||January 6, 2023||February 1, 2023|
|October 6, 2022||$0.54||October 7, 2022||November 1, 2022|
|June 30, 2022||$0.54||July 1, 2022||August 1, 2022|
|March 31, 2022||$0.54||April 1, 2022||May 2, 2022|
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.